WINDLAS BIOTECH
Windlas Biotech Share Price
Windlas Biotech Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in WINDLAS BIOTECH
Start SIPWindlas Biotech Investment Rating
-
Master Rating:
-
Windlas Biotech has an operating revenue of Rs. 474.91 Cr. on a trailing 12-month basis. An annual revenue growth of 10% is good, Pre-tax margin of 10% is healthy, ROE of 9% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 57 which is a POOR score indicating inconsistency in earnings, a RS Rating of 25 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 151 indicates it belongs to a poor industry group of Medical-Ethical Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 |
|---|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 120 | 122 | 118 | 115 | 111 | 107 |
| Operating Expenses Qtr Cr | 106 | 108 | 105 | 102 | 99 | 96 |
| Operating Profit Qtr Cr | 14 | 14 | 13 | 13 | 12 | 11 |
| Depreciation Qtr Cr | 3 | 3 | 3 | 3 | 3 | 3 |
| Interest Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax Qtr Cr | 4 | -1 | 3 | 3 | 3 | 2 |
| Net Profit Qtr Cr | 10 | 15 | 8 | 8 | 7 | 6 |
Windlas Biotech Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 0
- Bearish Moving Average
- ___
- 0
- 20 Day
- 233.36
- 50 Day
- 228.57
- 100 Day
- 229.76
- 200 Day
- 240.03
- 20 Day
- 235.79
- 50 Day
- 225.29
- 100 Day
- 223.59
- 200 Day
- 239.83
Windlas Biotech Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 234.74 |
| Second Resistance | 237.77 |
| Third Resistance | 239.89 |
| RSI | 48.64 |
| MFI | 69.37 |
| MACD Single Line | 4.28 |
| MACD | 2.72 |
| Support | |
|---|---|
| First Resistance | 229.59 |
| Second Resistance | 227.47 |
| Third Resistance | 224.44 |
Windlas Biotech Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 19,900 | 1,337,479 | 67.21 |
| Week | 33,838 | 1,881,077 | 55.59 |
| 1 Month | 101,281 | 5,357,740 | 52.9 |
| 6 Month | 50,495 | 2,675,716 | 52.99 |
Windlas Biotech Result Highlights
Windlas Biotech Synopsis
NSE-Medical-Ethical Drugs
Windlas Biotech belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 465.93 Cr. and Equity Capital is Rs. 10.90 Cr. for the Year ended 31/03/2022. Windlas Biotech Ltd. is a Public Limited Listed company incorporated on 19/02/2001 and has its registered office in the State of Uttarakhand/Uttaranchal, India. Company’s Corporate Identification Number(CIN) is L74899UR2001PLC033407 and registration number is 033407.| Market Cap | 502 |
| Sales | 475 |
| Shares in Float | 0.87 |
| No of funds | 15 |
| Yield | 1.52 |
| Book Value | 1.27 |
| U/D Vol ratio | 1.4 |
| LTDebt / Equity | |
| Alpha | -0.16 |
| Beta | 0.79 |
Windlas Biotech
| Owner Name | Jun-22 | Mar-22 | Dec-21 | Sep-21 |
|---|---|---|---|---|
| Promoters | 59.95% | 59.95% | 59.95% | |
| Mutual Funds | 11.9% | 9.5% | 9.9% | |
| Insurance Companies | 0.08% | 0.08% | 0.08% | |
| Foreign Portfolio Investors | 3.21% | 3.4% | 3.77% | |
| Financial Institutions/ Banks | 0.04% | 0.04% | 0.04% | |
| Individual Investors | 21.57% | 23.61% | 22.2% | |
| Others | 3.25% | 3.42% | 4.06% |
Windlas Biotech Management
| Name | Designation |
|---|---|
| Mr. Vivek Dhariwal | Chairman & Ind.Director |
| Mr. Hitesh Windlass | Managing Director |
| Mr. Manoj Kumar Windlass | Joint Managing Director |
| Mr. Pawan Kumar Sharma | Executive Director |
| Mr. Ashok Kumar Windlass | Whole Time Director |
| Mrs. Prachi Jain Windlass | Non Executive Director |
| Mr. Srinivasan Venkataraman | Ind. Non-Executive Director |
| Mr. Gaurav Gulati | Ind. Non-Executive Director |
Windlas Biotech Forecast
Price Estimates
Windlas Biotech Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2022-08-04 | Quarterly Results | |
| 2022-05-12 | Audited Results & Dividend | |
| 2022-02-02 | Quarterly Results | |
| 2021-11-01 | Quarterly Results | |
| 2021-09-08 | Quarterly Results |
Windlas Biotech FAQs
What is Share Price of Windlas Biotech ?
Windlas Biotech share price is ₹230 As on 30 September, 2022 | 03:14
What is the Market Cap of Windlas Biotech ?
The Market Cap of Windlas Biotech is ₹501.9 Cr As on 30 September, 2022 | 03:14
What is the P/E ratio of Windlas Biotech ?
The P/E ratio of Windlas Biotech is 12.2 As on 30 September, 2022 | 03:14
What is the PB ratio of Windlas Biotech ?
The PB ratio of Windlas Biotech is 1.3 As on 30 September, 2022 | 03:14